Click here to learn more about the underlying causes of PAH and our lead clinical product candidate, seralutinib »
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.
Phase 3 planned
*Targets to be disclosed